Fecal calprotectin

VTE is a serious, potentially preventable complication in children with newly diagnosed IBD. Identifying risk factors could help clinicians consider which pediatric patients might need closer monitoring or future...

Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.

The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...

If confirmed, a brain perivascular/glymphatic change linked to intestinal inflammation could help explain why sleep problems are common in Crohn's disease and point to new research targets for symptom mechanisms and...

The T&W criteria are still used to define severe UC on admission, but relying on them alone may delay recognition of steroid non‑response and escalation decisions. Integrating biomarkers, endoscopy, and imaging can help...

If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.

Faecal calprotectin appears to be the best non‑invasive test among those studied for distinguishing UC from Crohn’s disease and for reflecting mucosal inflammation. Simpler blood‑based scores may help gauge systemic...

Noninvasive stool metabolite patterns could eventually help predict which people with Crohn’s disease are more likely to develop strictures or penetrating complications, and may offer markers of disease activity and...

Bowel wall vascularization on ultrasound is used to gauge transmural inflammation in Crohn’s disease. This study examines whether quantitative measures could make those assessments more objective and how technique and...

Dietary strategies like the Mediterranean diet and time-restricted feeding could be low-risk ways to influence gut microbiota, short-chain fatty acids, and inflammation in people with ulcerative colitis; this trial will...

Measuring mucosal healing across the whole gut with stool markers, ultrasound, and capsule endoscopy may give a clearer picture of whether biologic treatment is working and help guide decisions about continuing or...

Oral signs such as persistent lip swelling can be an early presentation of Crohn’s disease in adolescents and may prompt testing that leads to earlier diagnosis and treatment.

Real‑world studies of ustekinumab help patients and clinicians understand how the drug performs outside clinical trials, including effectiveness for steroid‑free remission and use across different UK care settings.

Diet-based therapies like CDED + PEN may help control Crohn’s symptoms and improve nutrition without adding medications. This study suggests some adults can maintain remission and gain nutritional benefits over a year...

This study could validate a noninvasive stool-test strategy (FIT + fecal calprotectin) to triage which long-standing UC patients need colonoscopy, potentially improving surveillance efficiency and adherence.

The study provides real-world effectiveness and safety data for risankizumab in a largely difficult-to-treat Crohn's population, showing about half achieved corticosteroid-free clinical remission at 24 weeks —...

This study suggests that people with PSC-IBD may respond differently to some biologic treatments: infliximab and vedolizumab had similar early effectiveness versus IBD alone, but ustekinumab showed a lower early response...

This large pediatric registry study suggests children starting infliximab biosimilars have similar 12‑month clinical outcomes and treatment durability as those starting the originator drug — reassuring for patients and...

This trial tests whether pomegranate juice can lower fecal calprotectin, a commonly used marker of intestinal inflammation, in people with IBD in remission. If effective, such a dietary approach could be of interest to...

The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...

If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.

Noninvasive stool markers that track endoscopic inflammation could reduce the need for frequent pediatric endoscopies, easing burden and risk for children with IBD. Strong correlation with endoscopy suggests these tests...

For people with IBD who do not respond to standard biologic doses, escalating the dose appears common in routine care and was associated with better short-term remission rates and reduced healthcare use in this registry...

Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...

Early, noninvasive stool tests (fecal calprotectin and FIT) might identify whether vedolizumab or infliximab is likely to work within weeks instead of months. That could let patients and clinicians make treatment...

The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...

Diagnostic delays can mean a child with Crohn's disease doesn't get timely treatment. This report shows weight loss in young patients—especially girls—can be mistakenly labeled an eating disorder, so awareness and...

Noninvasive tools that reliably detect postoperative recurrence could reduce the need for frequent invasive endoscopy and help target earlier intervention for people with Crohn's disease after surgery.

The study suggests nickel accumulation and iron deficiency may be linked with more severe IBD. If confirmed, blood metal and micronutrient levels could help researchers understand disease mechanisms and guide nutritional...

If validated, an early drop in fecal calprotectin could help identify patients on biologic therapy who are likely to achieve mucosal healing without waiting for invasive endoscopy, allowing earlier decisions about...

If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.

Dietary therapy (CDED + PEN) was associated with longer remission when families adhered well; since adherence varies, support from a dietitian matters for keeping children in remission.

Fecal calprotectin measured by a point‑of‑care CGICA assay showed high accuracy for identifying colorectal inflammation and IBD in patients with chronic diarrhea, which could help avoid some unnecessary colonoscopies...

Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.

Fecal calprotectin is a noninvasive stool biomarker used to detect intestinal inflammation and to help distinguish IBD from noninflammatory conditions.

The study describes a new urine-based fluorescent biosensor that detected inflamed intestinal sites and tracked treatment response earlier and more sensitively than fecal calprotectin in a mouse model of IBD, which could...

Self‑management programs delivered by nurses may help people with IBD improve daily functioning, confidence in managing their condition, and quality of life even when inflammation markers don’t change. That matters...

Bowel urgency is a common symptom that may predict higher risk of treatment escalation, hospitalization, or surgery in UC even when bleeding and stool frequency look controlled. Better assessment of urgency in clinic...

Noninvasive monitoring matters for children with UC because endoscopy is burdensome. If ultrasound (and simple measures like bowel wall thickness) can reliably detect moderate-to-severe disease, families may avoid some...

Point-of-care intestinal ultrasound (IUS) showed strong agreement with follow-up tests and often changed management the same day in a New Zealand IBD cohort. Patients and clinicians may be able to use IUS to monitor...

Bowel urgency is a common, disruptive UC symptom; this trial analysis shows urgency improvements with etrasimod track with clinical remission, endoscopic improvement, better quality of life, and lower inflammatory...

Many patients and clinicians are interested in subcutaneous infliximab because it can be more convenient than IV infusions and may change drug exposure.

People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...

CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...

Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.

People with Crohn’s disease can have liver involvement that may be missed on routine exams. Quantitative liver MRI measures (fat fraction and extracellular volume) could help detect and monitor subtle liver injury...

This study suggests that higher intake of specific fibers (beta‑glucan and inulin) may be linked to lower Crohn’s risk in people with a family history, and it connects those fibers to biomarkers of inflammation, barrier...

Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.